Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.64 |
| ▸ | AURKA | O14965 | 12/20 | 0.64 |
| ▸ | TEK | Q02763 | 12/20 | 0.64 |
| ▸ | MET | P08581 | 11/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.64 |
| ▸ | LCK | P06239 | 8/20 | 0.60 |
| ▸ | LYN | P07948 | 3/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | FGR | P09769 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748193 | 0.88 | KDR (0.68) | KDRAURKATEKMETAURKB | |
| SCHEMBL3754606 | 0.88 | KDR (0.64) | KDRAURKATEKMETAURKB | |
| SCHEMBL2748969 | 0.88 | KDR (0.82) | KDRAURKATEKMETAURKB | |
| SCHEMBL5773976 | 0.87 | KDR (0.76) | KDRAURKATEKMETAURKB | |
| SCHEMBL2747032 | 0.84 | KDR (0.82) | KDRAURKATEKMETAURKB | |
| Hydrochloric Acid SCHEMBL2746794 | 0.84 | KDR (0.81) | KDRAURKATEKMETAURKB | |
| SCHEMBL5771547 | 0.81 | KDR (0.70) | KDRAURKATEKMETAURKB | |
| SCHEMBL2747857 | 0.80 | KDR (0.69) | KDRAURKATEKMETAURKB | |
| SCHEMBL30097451 | 0.80 | KDR (0.90) | KDRAURKATEKMETAURKB | |
| SCHEMBL2747776 | 0.80 | KDR (0.90) | KDRAURKATEKMETAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | KDR 30/4885AURKA 2306/4885TEK 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.